Home>
US Stocks>
Biocryst Pharmaceuticals Inc

Biocryst Pharmaceuticals Inc share price today

(BCRX)

Biocryst Pharmaceuticals Inc share price is $7.33 & ₹620.84

$7.33

▲

0.14

(1.95%)

Market is closed - opens 8 PM, 05 Dec 2024

View live Biocryst Pharmaceuticals Inc share price in Dollar and Rupees. Guide to invest in Biocryst Pharmaceuticals Inc from India. Also see the sentimental analysis on Indian investors investing in Biocryst Pharmaceuticals Inc. Get details on the Indian mutual funds that are investing in Biocryst Pharmaceuticals Inc. Get Analyst recommendations and forecasts along with all the Biocryst Pharmaceuticals Inc's financials.

Biocryst Pharmaceuticals Inc share price movements

$7.11
$7.56
$7.33
3.0%
Downside
Day's Volatility :5.95%
Upside
3.04%
$4.03
$8.88
$7.33
45.02%
Downside
52 Weeks Volatility :54.62%
Upside
17.45%

Biocryst Pharmaceuticals Inc Returns

Period	Biocryst Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-9.23%	-6.1%	0.0%
6 Months	14.6%	1.4%	0.0%
1 Year	33.94%	11.4%	0.0%
3 Years	-33.99%	12.9%	-18.1%

Biocryst Pharmaceuticals Inc Key Statistics

in dollars & INR

Market Capitalization	$1.6B
Revenue TTM	$412.6M
EBITDA	$-31.9M
Earnings Per Share (EPS)	$-0.61
Profit Margin	-30.01%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1925.37%

How to invest in Biocryst Pharmaceuticals Inc from India?

It is very easy for Indian residents to invest directly in Biocryst Pharmaceuticals Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biocryst Pharmaceuticals Inc stock in both rupees (INR) and dollars (USD). Search for Biocryst Pharmaceuticals Inc or BCRX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biocryst Pharmaceuticals Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biocryst Pharmaceuticals Inc shares which would translate to 0.116 fractional shares of Biocryst Pharmaceuticals Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Biocryst Pharmaceuticals Inc

50%

Period: Sep 5, 2024 to Dec 4, 2024. Change in 30 Days versus previous period

Search volume for Biocryst Pharmaceuticals Inc on INDmoney from India has grown in the last 30 days as on Dec 5, 2024. 50% more investors are searching Biocryst Pharmaceuticals Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Biocryst Pharmaceuticals Inc

Vanguard Group Inc
9.80%
BlackRock Inc
9.63%
venBio Select Advisor LLC
5.73%
Kynam Capital Management, LP
4.39%
State Street Corp
4.27%
Deerfield Management Co
3.93%

Analyst Recommendation on Biocryst Pharmaceuticals Inc

Buy

83%Buy

16%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Biocryst Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Based on 18 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biocryst Pharmaceuticals Inc

What analysts predicted

Upside of 99.68%

Current:

$7.33

Target:

$14.64

Insights on Biocryst Pharmaceuticals Inc

Increasing Revenue
Revenue is up for the last 3 quarters, 92.76M → 117.08M (in $), with an average increase of 10.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -12.67M → -14.03M (in $), with an average decrease of 10.7% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 46.4% return, outperforming this stock by 27.2%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.6% return, outperforming this stock by 83.1%

Biocryst Pharmaceuticals Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$20.7M	↓ 18.0%
Net Income	$-101.3M	↑ 53.92%
Net Profit Margin	-490.25%	↓ 229.07%

	FY19	Y/Y Change
Revenue	$48.8M	↑ 136.45%
Net Income	$-120.1M	↑ 18.58%
Net Profit Margin	-245.86%	↑ 244.39%

	FY20	Y/Y Change
Revenue	$17.8M	↓ 63.53%
Net Income	$-196.6M	↑ 63.72%
Net Profit Margin	-1.1K%	↓ 857.71%

	FY21	Y/Y Change
Revenue	$157.2M	↑ 782.38%
Net Income	$-184.1M	↓ 6.36%
Net Profit Margin	-117.11%	↑ 986.46%

	FY22	Y/Y Change
Revenue	$270.8M	↑ 72.31%
Net Income	$-247.1M	↑ 34.26%
Net Profit Margin	-91.25%	↑ 25.86%

	FY23	Y/Y Change
Revenue	$331.4M	↑ 22.37%
Net Income	$-226.5M	↓ 8.33%
Net Profit Margin	-68.36%	↑ 22.89%

	Q2 FY23	Q/Q Change
Revenue	$82.5M	↑ 19.94%
Net Income	$-75.3M	↑ 41.24%
Net Profit Margin	-91.31%	↓ 13.77%

	Q3 FY23	Q/Q Change
Revenue	$86.7M	↑ 5.15%
Net Income	$-36.1M	↓ 52.01%
Net Profit Margin	-41.67%	↑ 49.64%

	Q4 FY23	Q/Q Change
Revenue	$93.4M	↑ 7.68%
Net Income	$-61.7M	↑ 70.77%
Net Profit Margin	-66.09%	↓ 24.42%

	Q1 FY24	Q/Q Change
Revenue	$92.8M	↓ 0.69%
Net Income	$-35.4M	↓ 42.69%
Net Profit Margin	-38.14%	↑ 27.95%

	Q2 FY24	Q/Q Change
Revenue	$109.3M	↑ 17.86%
Net Income	$-12.7M	↓ 64.18%
Net Profit Margin	-11.59%	↑ 26.55%

	Q3 FY24	Q/Q Change
Revenue	$117.1M	↑ 7.09%
Net Income	$-14.0M	↑ 10.72%
Net Profit Margin	-11.99%	↓ 0.4%

	FY18	Y/Y Change
Total Assets	$146.8M	↓ 17.62%
Total Liabilities	$97.6M	↑ 3.3%

	FY19	Y/Y Change
Total Assets	$175.3M	↑ 19.37%
Total Liabilities	$137.0M	↑ 40.39%

	FY20	Y/Y Change
Total Assets	$334.7M	↑ 90.96%
Total Liabilities	$354.0M	↑ 158.32%

	FY21	Y/Y Change
Total Assets	$588.2M	↑ 75.72%
Total Liabilities	$695.1M	↑ 96.38%

	FY22	Y/Y Change
Total Assets	$550.0M	↓ 6.49%
Total Liabilities	$844.6M	↑ 21.5%

	FY23	Y/Y Change
Total Assets	$517.0M	↓ 6.01%
Total Liabilities	$972.5M	↑ 15.14%

	Q2 FY23	Q/Q Change
Total Assets	$529.9M	↑ 3.95%
Total Liabilities	$918.6M	↑ 9.61%

	Q3 FY23	Q/Q Change
Total Assets	$-685.5M	↓ 229.37%
Total Liabilities	$933.9M	↑ 1.67%

	Q4 FY23	Q/Q Change
Total Assets	$517.0M	↓ 175.41%
Total Liabilities	$972.5M	↑ 4.13%

	Q1 FY24	Q/Q Change
Total Assets	$467.9M	↓ 9.49%
Total Liabilities	$944.1M	↓ 2.92%

	Q2 FY24	Q/Q Change
Total Assets	$472.4M	↑ 0.97%
Total Liabilities	$948.0M	↑ 0.42%

	Q3 FY24	Q/Q Change
Total Assets	$491.3M	↑ 3.99%
Total Liabilities	$959.8M	↑ 1.24%

	FY18	Y/Y Change
Operating Cash Flow	$-92.6M	↑ 124.98%
Investing Cash Flow	$4.8M	↓ 107.18%
Financing Cash Flow	$62.5M	↓ 53.94%

	FY19	Y/Y Change
Operating Cash Flow	$-89.6M	↓ 3.22%
Investing Cash Flow	$77.9M	↑ 1534.52%
Financing Cash Flow	$99.1M	↑ 58.55%

	FY20	Y/Y Change
Operating Cash Flow	$-137.2M	↑ 53.17%
Investing Cash Flow	$-6.9M	↓ 108.8%
Financing Cash Flow	$302.7M	↑ 205.45%

	FY21	Y/Y Change
Operating Cash Flow	$-142.2M	↑ 3.6%
Investing Cash Flow	$15.8M	↓ 330.51%
Financing Cash Flow	$359.7M	↑ 18.82%

	FY22	Y/Y Change
Operating Cash Flow	$-161.9M	↑ 13.85%
Investing Cash Flow	$-128.2M	↓ 911.43%
Financing Cash Flow	$88.0M	↓ 75.53%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-18.8M	↓ 60.4%
Investing Cash Flow	$-19.0M	↓ 82.23%
Financing Cash Flow	$29.4M	↑ 478.22%

Biocryst Pharmaceuticals Inc Technicals Summary

Sell

Neutral

Buy

Biocryst Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Biocryst Pharmaceuticals Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biocryst Pharmaceuticals Inc	0.41%	14.6%	33.94%	-33.99%	182.76%
Regeneron Pharmaceuticals, Inc.	-8.02%	-23.83%	-8.78%	21.97%	108.5%
Biontech Se	7.55%	15.12%	15.65%	-58.12%	304.14%
Alnylam Pharmaceuticals, Inc.	-6.28%	69.46%	44.56%	42.94%	109.6%
Vertex Pharmaceuticals Incorporated	-1.5%	-4.08%	31.76%	127.12%	112.3%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biocryst Pharmaceuticals Inc	NA	NA	-0.28	-0.36	-19.25	-0.04	NA	-2.26
Regeneron Pharmaceuticals, Inc.	18.55	18.55	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biocryst Pharmaceuticals Inc	Buy	$1.6B	182.76%	NA	-30.01%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	108.5%	18.55	33.61%
Biontech Se	Buy	$28.9B	304.14%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	109.6%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	112.3%	32.84	-4.51%

About Biocryst Pharmaceuticals Inc

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.

Organization	Biocryst Pharmaceuticals Inc
Employees	536
CEO	Mr. Jon P. Stonehouse
Industry	Health Technology

Important FAQs about investing in Biocryst Pharmaceuticals Inc from India :

What is Biocryst Pharmaceuticals Inc share price today?

Biocryst Pharmaceuticals Inc (BCRX) share price today is $7.33.

Can Indians buy Biocryst Pharmaceuticals Inc shares?

Yes, Indians can invest in the Biocryst Pharmaceuticals Inc (BCRX) from India.

With INDmoney, you can buy Biocryst Pharmaceuticals Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biocryst Pharmaceuticals Inc at zero transaction cost.

How can I buy Biocryst Pharmaceuticals Inc shares from India?

It is very easy to buy Biocryst Pharmaceuticals Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biocryst Pharmaceuticals Inc be purchased?

Yes, you can buy fractional shares of Biocryst Pharmaceuticals Inc with INDmoney app.

What are the documents required to start investing in Biocryst Pharmaceuticals Inc stocks?

To start investing in Biocryst Pharmaceuticals Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.